×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AIM – aim immunotech inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AIM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/18
09:18 am
aim
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors [Yahoo! Finance]
High
Report
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors [Yahoo! Finance]
3/18
08:36 am
aim
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
High
Report
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
3/6
07:25 pm
aim
AIM ImmunoTech Announces Closing of its Rights Offering [Yahoo! Finance]
Low
Report
AIM ImmunoTech Announces Closing of its Rights Offering [Yahoo! Finance]
3/6
07:00 pm
aim
AIM ImmunoTech Announces Closing of its Rights Offering
Low
Report
AIM ImmunoTech Announces Closing of its Rights Offering
3/4
09:15 am
aim
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million [Yahoo! Finance]
Low
Report
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million [Yahoo! Finance]
3/4
09:00 am
aim
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
Low
Report
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
3/2
09:00 am
aim
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
High
Report
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
2/27
09:00 am
aim
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
Medium
Report
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/16
05:30 pm
aim
Form 4 AIM ImmunoTech Inc. For: Mar 16 Filed by: CHEMEROW DAVID I.
Low
Report
Form 4 AIM ImmunoTech Inc. For: Mar 16 Filed by: CHEMEROW DAVID I.
3/16
05:30 pm
aim
Form 4 AIM ImmunoTech Inc. For: Mar 16 Filed by: Equels Thomas K
Low
Report
Form 4 AIM ImmunoTech Inc. For: Mar 16 Filed by: Equels Thomas K
3/10
05:57 pm
aim
Form 4 AIM ImmunoTech Inc. For: Mar 06 Filed by: CHEMEROW DAVID I.
Medium
Report
Form 4 AIM ImmunoTech Inc. For: Mar 06 Filed by: CHEMEROW DAVID I.
3/10
05:57 pm
aim
Form 4 AIM ImmunoTech Inc. For: Mar 06 Filed by: Equels Thomas K
Medium
Report
Form 4 AIM ImmunoTech Inc. For: Mar 06 Filed by: Equels Thomas K
3/6
05:16 pm
aim
Form 8-K AIM ImmunoTech Inc. For: Mar 04
Low
Report
Form 8-K AIM ImmunoTech Inc. For: Mar 04
2/27
08:30 am
aim
Form 424B3 AIM ImmunoTech Inc.
Medium
Report
Form 424B3 AIM ImmunoTech Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/9
AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19
169.9%
9/24 Form S-1/A AIM ImmunoTech Inc. 48.2%
3/3 Form 424B5 AIM ImmunoTech Inc. 32.2%
2/11 AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus 26.2%
2/12 AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus 19.0%
9/19 AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer 18.9%
3/10 Form 424B5 AIM ImmunoTech Inc. 15.7%
12/2 Form 4 AIM ImmunoTech Inc. For: Nov 29 Filed by: EQUELS THOMAS K. 15.6%
11/1 Form 4 AIM ImmunoTech Inc. For: Oct 31 Filed by: APPELROUTH STEWART 13.8%
4/27 Form 8-K AIM ImmunoTech Inc. For: Apr 27 13.6%
9/24 Form S-1/A AIM ImmunoTech Inc. 48.2%
3/3 Form 424B5 AIM ImmunoTech Inc. 32.2%
2/11 AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus 26.2%
2/12 AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus 19.0%
9/19 AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer 18.9%
3/10 Form 424B5 AIM ImmunoTech Inc. 15.7%
12/2 Form 4 AIM ImmunoTech Inc. For: Nov 29 Filed by: EQUELS THOMAS K. 15.6%
11/1 Form 4 AIM ImmunoTech Inc. For: Oct 31 Filed by: APPELROUTH STEWART 13.8%
4/27 Form 8-K AIM ImmunoTech Inc. For: Apr 27 13.6%
TOP News Decliners
9/25
Form S-1/A AIM ImmunoTech Inc.
-44.1%
9/19 AIM Immunotech up 105% premarket after DOD grant for cancer study [Seeking Alpha] -32.3%
2/11 Form 8-K AIM ImmunoTech Inc. For: Feb 11 -28.4%
3/31 AIM ImmunoTech Reports 2019 Year-end Financial Results -24.9%
9/26 Form EFFECT AIM ImmunoTech Inc. -15.3%
2/18 Form 8-K AIM ImmunoTech Inc. For: Feb 18 -12.0%
9/24 Form 8-K AIM ImmunoTech Inc. For: Sep 19 -8.9%
4/6 AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic -8.1%
12/4 Form 8-K AIM ImmunoTech Inc. For: Dec 04 -7.9%
10/10 AIM ImmunoTech Inc. (NYSE: AIM) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. -7.7%
9/19 AIM Immunotech up 105% premarket after DOD grant for cancer study [Seeking Alpha] -32.3%
2/11 Form 8-K AIM ImmunoTech Inc. For: Feb 11 -28.4%
3/31 AIM ImmunoTech Reports 2019 Year-end Financial Results -24.9%
9/26 Form EFFECT AIM ImmunoTech Inc. -15.3%
2/18 Form 8-K AIM ImmunoTech Inc. For: Feb 18 -12.0%
9/24 Form 8-K AIM ImmunoTech Inc. For: Sep 19 -8.9%
4/6 AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic -8.1%
12/4 Form 8-K AIM ImmunoTech Inc. For: Dec 04 -7.9%
10/10 AIM ImmunoTech Inc. (NYSE: AIM) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: